Quantum BioPharma Ltd. (QNTM) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Quantum BioPharma Ltd. stock (QNTM) is currently trading at $4.73. Quantum BioPharma Ltd. PS ratio (Price-to-Sales) is 91.86. Analyst consensus price target for QNTM is $44.92. WallStSmart rates QNTM as Sell.
- QNTM PE ratio analysis and historical PE chart
- QNTM PS ratio (Price-to-Sales) history and trend
- QNTM intrinsic value — DCF, Graham Number, EPV models
- QNTM stock price prediction 2025 2026 2027 2028 2029 2030
- QNTM fair value vs current price
- QNTM insider transactions and insider buying
- Is QNTM undervalued or overvalued?
- Quantum BioPharma Ltd. financial analysis — revenue, earnings, cash flow
- QNTM Piotroski F-Score and Altman Z-Score
- QNTM analyst price target and Smart Rating
Quantum BioPharma
📊 No data available
Try selecting a different time range
Smart Analysis
Quantum BioPharma Ltd. (QNTM) · 5 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Quantum BioPharma Ltd. (QNTM) Key Strengths (1)
Trading below book value, meaning the market prices it less than net assets
Supporting Valuation Data
Quantum BioPharma Ltd. (QNTM) Areas to Watch (4)
Company is destroying shareholder value
Very expensive at 91.9x annual revenue
Very low institutional interest at 14.33%
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Quantum BioPharma Ltd. (QNTM) Detailed Analysis Report
Overall Assessment
This company scores 19/100 in our Smart Analysis, earning a F grade. Out of 5 metrics analyzed, 1 register as strengths (avg 10.0/10) while 4 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book. Valuation metrics including Price/Book (0.98) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Price/Sales, Institutional Own.. Some valuation metrics including Price/Sales (91.86) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -251.30%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -251.30% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Sales are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
QNTM Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
QNTM's Price-to-Sales ratio of 91.86x sits near its historical average of 91.86x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 0% below its historical high of 91.86x set in Mar 2026, and 0% above its historical low of 91.86x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Quantum BioPharma Ltd. (QNTM) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Quantum BioPharma Ltd. operates as a stable business with moderate growth and solid fundamentals.
Key Findings
Debt-to-equity ratio of 0.30 indicates a conservative balance sheet with 445,944 in cash.
Free cash flow is -2M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Debt management: total debt of 3M is significantly higher than cash (445,944). Monitor refinancing risk.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Quantum BioPharma Ltd..
Bottom Line
Quantum BioPharma Ltd. offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 11:50:05 AM
About Quantum BioPharma Ltd.(QNTM)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Quantum BioPharma Ltd. (QNTM) is an innovative biotechnology company focused on developing groundbreaking therapies for complex medical conditions, particularly in underserved areas such as oncology and autoimmune disorders. With a robust pipeline of advanced biopharmaceutical products, the company leverages cutting-edge technologies and a commitment to rigorous research and development. Quantum BioPharma’s strategic partnerships and a seasoned leadership team enhance its potential to capitalize on the growing demand for novel therapeutics, positioning it as a compelling investment opportunity within the dynamic biopharmaceutical landscape.